Phase 3 Schizophrenia trials recruiting now

All Schizophrenia trials, every phase

Other phases for Schizophrenia

Phase 3 Schizophrenia trials

• 52-week Open Label Safety-Tolerability Study
  NCT07369154 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 23 locations
• A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
  NCT07225712 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 293 locations
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 44 locations
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
  NCT07288567 · Phase: Phase 3 · Ages: 13 Years to 17 Years · Sex: All (male and female) · 38 locations
• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
  NCT06882785 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 56 locations
• A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
  NCT07424404 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · 91 locations
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
  NCT06894212 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 73 locations
• An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
  NCT03094429 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
  NCT06351514 · Phase: Phase 3 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 1 location
• Cognitive Strategies in Early Psychosis 1
  NCT07231497 · Phase: Phase 3 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 1 location
• Cognitive Strategies in Early Psychosis 2
  NCT07263022 · Phase: Phase 3 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 1 location
• Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
  NCT04411225 · Phase: Phase 3 · Ages: 16 Years to 30 Years · Sex: All (male and female) · 2 locations
• Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
  NCT03817502 · Phase: Phase 3 · Ages: 13 Years to 17 Years · Sex: All (male and female) · 57 locations
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
  NCT07227818 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 20 locations
• Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
  NCT05796401 · Phase: Phase 3 · Ages: 15 Years to 30 Years · Sex: All (male and female) · 13 locations
• Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
  NCT05669742 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
  NCT07184619 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
  NCT05603104 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
  NCT06529029 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
  NCT06482554 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
  NCT07045142 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 8 locations
• MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
  NCT06191965 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 3 locations
• NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
  NCT06963034 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 21 locations
• NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
  NCT07105098 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 15 locations
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
  NCT07114874 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 57 locations
• No Guts No Glory Probiotics
  NCT07606014 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• Randomized Withdrawal Study in Patients With Schizophrenia
  NCT06961968 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 22 locations
• Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
  NCT07686263 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 59 locations
• Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
  NCT05184335 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 18 locations
• Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
  NCT06229210 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · 64 locations
• Stratification and Treatment in Early Psychosis Study - ENHANCE
  NCT06778564 · Phase: Phase 3 · Ages: 16 Years to 40 Years · Sex: All (male and female) · 17 locations
• Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
  NCT07565428 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 13 locations
• Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
  NCT07363577 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 13 locations
• Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
  NCT05303064 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 47 locations
• Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
  NCT05325645 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.